These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 24380964)

  • 1. [Relapse prevention in drug addicts].
    Rácz J
    Neuropsychopharmacol Hung; 2013 Dec; 15(4):232-8. PubMed ID: 24380964
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel pharmacotherapeutic targets for the management of drug addiction.
    Heidbreder C
    Eur J Pharmacol; 2005 Dec; 526(1-3):101-12. PubMed ID: 16253234
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Cognitive impairments in psychoactive drug addicts].
    Chukhlovina ML
    Zh Nevrol Psikhiatr Im S S Korsakova; 2015; 115(6):83-85. PubMed ID: 26438897
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Can drug users be effective change agents? Yes, but much still needs to change.
    Dickson-Gomez J
    Subst Use Misuse; 2010; 45(1-2):154-60. PubMed ID: 20025444
    [No Abstract]   [Full Text] [Related]  

  • 5. Anticraving medications for relapse prevention: a possible new class of psychoactive medications.
    O'Brien CP
    Am J Psychiatry; 2005 Aug; 162(8):1423-31. PubMed ID: 16055763
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cognitive-Behavioral Therapy.
    An H; He RH; Zheng YR; Tao R
    Adv Exp Med Biol; 2017; 1010():321-329. PubMed ID: 29098680
    [TBL] [Abstract][Full Text] [Related]  

  • 7. From Abstinence to Relapse: A Preliminary Qualitative Study of Drug Users in a Compulsory Drug Rehabilitation Center in Changsha, China.
    Yang M; Mamy J; Gao P; Xiao S
    PLoS One; 2015; 10(6):e0130711. PubMed ID: 26107639
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Web-based cognitive behavioral relapse prevention program with tailored feedback for people with methamphetamine and other drug use problems: protocol for a multicenter randomized controlled trial in Japan.
    Takano A; Miyamoto Y; Kawakami N; Matsumoto T; Shinozaki T; Sugimoto T
    BMC Psychiatry; 2016 Apr; 16():87. PubMed ID: 27044304
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treating Addictions: Harm Reduction in Clinical Care and Prevention.
    Drucker E; Anderson K; Haemmig R; Heimer R; Small D; Walley A; Wood E; van Beek I
    J Bioeth Inq; 2016 Jun; 13(2):239-49. PubMed ID: 27112489
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Development of a manualized cognitive behavioral therapy program for Japanese drug addicts and a study of the efficacy of the program].
    Morita N; Suetsugu S; Shimane T; Okasaka Y; Kiyoshige T; Iwai K
    Nihon Arukoru Yakubutsu Igakkai Zasshi; 2007 Oct; 42(5):487-505; quiz 506. PubMed ID: 18051469
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Relapse prevention program for drug addicts in center for mental health and welfare].
    Miyazaki Y; Yamaguchi A; Kondo A; Igarashi M; Yottsuji N; Takahashia I
    Nihon Arukoru Yakubutsu Igakkai Zasshi; 2010 Apr; 45(2):119-27. PubMed ID: 20486563
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Cartography of psychoactive heterotopias: a look at the medical, legal and social discourses regarding drug use].
    Massó P
    Salud Colect; 2015 Sep; 11(3):381-99. PubMed ID: 26418094
    [TBL] [Abstract][Full Text] [Related]  

  • 13. G. Alan Marlatt: 1941-2011.
    Miller WR; McLellan AT
    J Subst Abuse Treat; 2011 Dec; 41(4):331-4. PubMed ID: 21831560
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Efficacy of the Serigaya Methamphetamine Relapse Prevention Program (SMARPP): for patients with drug use disorder: A study on factors influencing 1-year follow-up outcomes].
    Tanibuchi Y; Matsumoto T; Imamura F; Wakabayashi A; Kawachi H; Hikitsuchi E; Takano A; Yonezawa M; Kato T; Yamada M; Wachi A; Aboshi M; Wada K
    Nihon Arukoru Yakubutsu Igakkai Zasshi; 2016 Feb; 51(1):38-54. PubMed ID: 27295823
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New psychoactive substances: Current health-related practices and challenges in responding to use and harms in Europe.
    Pirona A; Bo A; Hedrich D; Ferri M; van Gelder N; Giraudon I; Montanari L; Simon R; Mounteney J
    Int J Drug Policy; 2017 Feb; 40():84-92. PubMed ID: 27956184
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chapter 11. Narratives of clients' experiences of drug use and treatment of substance use-related dependency.
    von Braun T; Larsson S; Sjöblom Y
    Subst Use Misuse; 2013 Nov; 48(13):1404-15. PubMed ID: 24087873
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Factors associated with dropout from a group cognitive behavioral therapy for substance use disorder].
    Iwano S; Takahashi Y; Masuyama K; Yoshinari Y; Horiuchis S; Yanbe K
    Nihon Arukoru Yakubutsu Igakkai Zasshi; 2013 Dec; 48(6):415-25. PubMed ID: 24660557
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Self-concept mediate the relationship between childhood maltreatment and abstinence motivation as well as self-efficacy among drug addicts.
    Lu FY; Wen S; Deng G; Tang YL
    Addict Behav; 2017 May; 68():52-58. PubMed ID: 28088744
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Harm reduction interventions in drug users: current situation and recommendations].
    Bosque-Prous M; Brugal MT
    Gac Sanit; 2016 Nov; 30 Suppl 1():99-105. PubMed ID: 27837802
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New psychoactive substances: Are there any good options for regulating new psychoactive substances?
    Reuter P; Pardo B
    Int J Drug Policy; 2017 Feb; 40():117-122. PubMed ID: 27889115
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.